Adaptimmune Therapeutics plc announced the appointment of Dr. Elliot Norry as Senior Vice President and Chief Medical Officer (CMO) effective immediately, and additional changes to its R&D organization. Dr. Norry has served as Head of Clinical Safety and Pharmacovigilance and leader of the ADP-A2AFP program since 2015. He has been acting Chief Medical Officer since August 2019. Changes to the R&D leadership include an Early Stage Development group, led by Mark Dudley, will evaluate therapies in Phase 1 studies for safety as well as determining their potential for efficacy and further clinical development. Mark becomes Senior Vice President (SVP), Early Stage Development and previously served as SVP, Product Development; A Late Stage Development group, led by Dennis Williams, will take products through Phase 2/3 trials and registration. The first of these trials is SPEARHEAD-1 with ADP-A2M4 – currently open for recruitment of patients with synovial sarcoma or myxoid/round cell liposarcoma. Dennis has been promoted to SVP, Late Stage Development and will continue leading the regulatory affairs team; Joanna Brewer has been promoted to SVP, Allogeneic Research and will continue leading the allogeneic discovery work; and The Pipeline Research team will continue to be led by Karen Miller, SVP Pipeline Research.